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Abstract
In this paper we review clinical and genetic aspects of testicular germ cell tumours (TGCTs). TGCT is the most
common type of malignant disorder in men aged 15-40 years. Its incidence has increased sharply in recent
years. Fortunately, survival of patients with TGCT has improved enormously, which can chiefly be attributed to
the cisplatin-based polychemotherapy that was introduced in the nineteen eighties to treat patients with
metastasized TGCT. In addition, new strategies have been developed in the surgical approach to
metastasized/non-metastasized TGCT and alterations have been made to the radiotherapy technique and
radiation dose for seminoma. Family history of TGCT is among the strongest risk factors for this tumour type.
Although this fact and others suggest the existence of genetic predisposition to develop TGCT, no germline
mutations conferring high risk of developing TGCT have been identified so far. A small deletion, referred to as
gr/gr, identified on the Y chromosome is probably associated with only a modest increase in TGCT risk, and
linkage of familial TGCT to the Xq27 region has not been confirmed yet. Whether highly penetrant TGCT-
predisposing mutations truly exist or familial clustering of TGCT can be explained by combinations of weak
predispositions, shared in utero or postnatal risks factors and coincidental somatic mutations is an intriguing
puzzle, still waiting to be solved.
Introduction
Testicular tumours can be divided into germ cell
tumours, stromal tumours and other tumours (e.g.
malignant lymphomas). Tumours of paratesticular
structures form a separate group. This review focuses
solely on the testicular germ cell tumours (TGCT)
seminoma and non-seminoma. TGCT are rare, but
they are the most frequently occurring tumour in men
aged between 15 and 40 years. In the Netherlands,
536 men were diagnosed with TGCT in 2003, while
in 2004, 30 men died of this malignancy. Although the
incidence of TGCT has increased sharply in recent
years, survival of patients with TGCT has improved
enormously. Five-year survival in the nineteen seventies
was about 65% compared to more than 90% at
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present [1]. Improved survival can chiefly be attributed
to the cisplatin-based polychemotherapy that was
introduced in the nineteen eighties to treat patients with
metastasized TGCT. In addition, new strategies have
been developed in the surgical approach to
metastasized/non-metastasized TGCT and alterations
have been made to the radiotherapy technique and
radiation dose for seminoma [2, 3]. The progress in
diagnosis, treatment and the subsequent treatment
outcomes in patients with TGCT are the ultimate result
of multidisciplinary teamwork. At the University Medical
Center Groningen (UMCG), this multidisciplinary
approach was started at the end of the nineteen
seventies to provide every patient with tailored
treatment. These accomplishments in the treatment of
TGCT have led to the present goal of further optimising
the treatment for TGCT, in which the research and
treatment chiefly concentrate on reducing the toxic side-
effects of chemotherapy and radiotherapy. In patients
with prognostically favourable factors (Table 1) [4], the
number of courses of chemotherapy can be reduced,
whereas in patients with prognostically unfavourable
factors, more intensive chemotherapy is necessary to
improve the chances of survival. Nowadays the majority
of TGCT patients can be cured by multidisciplinary
treatment. Therefore, the number of TGCT survivors
will continue to increase. In principle, these TGCT
survivors will be exposed to the long-term consequences
of chemotherapy-related toxicity (side-effects) or the
long-term side-effects of radiotherapy. TGCT survivors
are mostly young men who can be expected to have
a long life ahead of them. This has meant that over the
past few years, scientific research has centred on
studying the long-term effects of treatment [5-8] and
the quality of life of these TGCT survivors [9]. All this
research has the ultimate aim of achieving further
improvement in the treatment and follow-up of TGCT
patients.
The somatic genetic background of TGCT
Carcinoma in situ (CIS) (or intratubular germ cell
neoplasia) is the precursor of TGCT and is found in
nearly all TGCT together with an invasive component.
CIS cells originate from primordial germ cells that
“escaped” normal differentiation in utero. It is assumed
that over the course of time, CIS “develops” into an
invasive TGCT, but the precise transformation of
premalignant CIS into a TGCT is not yet clear. It is
suggested that the default pathway follows the
development of CIS into seminoma and that non-
seminoma requires activation of pluripotency
Table 1. IGCCCG prognostic classification for germ cell cancer [4]
Prognosis Non-seminoma Seminoma
good testis/retroperitoneal primary any primary site
and and
no non-pulmonary visceral metastases no non-pulmonary visceral 
and metastases
AFP <1000 ng/ml and and
hCG <1000 ng/ml and normal AFP, any hCG, any LDH
LDH <1.5 × N*
intermediate testis/retroperitoneal primary any primary site
and and
no non-pulmonary visceral metastases non-pulmonary visceral
and metastases 
1000≤ AFP ≤10 000 ng/ml or and
1000≤ hCG ≤10 000 ng/ml or normal AFP, any hCG, any LDH
1.5 × N ≤ LDH ≤10 × N




AFP >10 000 ng/ml or
hCG >10 000 ng/ml or
LDH >10 × N
*N – normal range
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(reprogramming) of a CIS or seminoma cell [10, 11].
A theoretical model of TGCT development as part of
testicular dysgenesis, taking into account a range of
reported TGCT risk factors, has been developed by
Skaekebaek et al. [12] and is referred to as the
testicular dysgenesis syndrome (TDS) (Figure 1). In
recent years several studies have looked into
chromosomal abnormalities and more recently at gene
mutations and gene activity in TGCT to unravel the
molecular pathways underlying these tumours. 
A detailed overview of (non-inherited) genomic
aberrations in TGCT was recently published by von
Eyben [13]. Aneuploidy has been found in nearly all
cases and triploidy is a common finding. Seminomas
have a mean hypertriploid DNA index and non-
seminomas have a mean hypotriploid DNA index (due
to loss of chromosomal material during cancer
progression) [11]. When looking at individual
chromosomal regions, an isochromosome of the short
arm of chromosome 12, i(12p), (resulting in 
a duplication of the short arm of chromosome 12) is
found in about 80% of TGCT. The remainder have
excess 12p genetic material in derivative chromosomes
[14]. The exact relation between these changes and
TGCT is unclear but the absence of amplification of 
a section of 12p in intratubular germ cell neoplasia
suggests that this amplification may be related to
progression of the disease rather than initiation [15].
A recent gene expression profile study on TGCT
material identified differentiated expressed genes on
12p. Seventy-three genes on 12p were significantly
overexpressed, indicating that the p arm of
chromosome 12 may play an important role in TGCT
tumorigenesis [16]. In addition to the genes located
on 12p, a growing list of genes is implicated in the
various stages of TGCT development. In particular,
TGCT has been shown to be associated with 
a characteristic series of abnormalities in the
retinoblastoma pathway including upregulation of cyclin
D2 and p27 and downregulation of RB1 and the
cyclin-dependent kinase inhibitors of p16, p18, p19
and p21 [13]. A gain of activity of the KIT gene, 
a member of the tyrosine kinase family, appears to play
a role in the progression of CIS towards seminomas
[17]. Recently, the scope of genetic study of TGCT has
been extended to include the role of naturally occurring
micro RNAs (miRNAs). Indeed, some of these miRNAs
(miRNA-372 and 373) were shown to allow
tumorigenic growth. As they have also been observed























*possibly cryptorchidism (testicular maldescent) acts as a causal risk factor (for details, see discussion)
CIS – carcinoma in situ
Modified from Skakkebaek et al. [12] © European Society of Human Reproduction and Embryology. Reproduced with permission
Figure 1. The testicular dysgenesis syndrome
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seminomas, but not in normal testicular tissue, it has
been suggested that these miRNAs may represent 
a new class of oncogenes involved in TGCT [18].
Histology
TGCT can be divided into two important
histological subtypes: seminoma and non-seminoma.
Pure seminoma occurs in about 50% of cases and
often (in 20%) contains trophoblastic giant cells that
can produce beta-human chorionic gonadotrophin 
(β-HCG). Non-seminoma chiefly comprises two or
more cell types, for example embryonal carcinoma,
choriocarcinoma (also contains trophoblastic giant
cells), yolk sac tumour, and teratoma, whether or not
in combination with seminoma. Embryonal carcinoma
and yolk sac tumour elements are associated with the
production of alpha-fetoprotein (AFP). Clinically, there
are three important tumour markers in the diagnosis
and follow-up of TGCT: β-HCG, α-fetoprotein (AFP)
and lactate dehydrogenase (LDH) [2].
Clinical presentation and initial therapy
Patients who present with a painless swelling of the
testicle and increased levels of AFP, β-HCG and/or LDH
have a TGCT until proven otherwise. Clinical
presentation varies widely. TGCT can also show extra-
testicular clinical manifestation (without any testicular
complaints). Retroperitoneal lymph node metastases can
cause (lower) back pain, while haemoptysis can be the
result of pulmonary metastases. Ultrasound examination
of the testicle is useful to establish possible testicular
abnormalities. Radical inguinal orchidectomy with high
ligation of the spermatic cord, blood vessels and lymph
vessels is the surgical treatment for patients who are
suspected of having a TGCT. Originally, the testicles
descend via the retroperitoneal route and inguinal canal
into the scrotum. This often results in regional metastases
from a TGCT that first arise in the retroperitoneal lymph
nodes. A right-sided TGCT tends to metastasize to the
interaortocaval lymph nodes, whereas a left-sided TGCT
tends to metastasize to the para-aortic lymph nodes. At
a higher, supradiaphragmatic level, metastases can
spread via the thoracic duct and result in mediastinal or
supraclavicular metastases. Haematogenically, TGCT
chiefly metastasize to the lungs, later to the liver, the
skeleton and the cerebrum [3, 19].
Staging
When a patient has been diagnosed with a TGCT,
the malignancy must be staged. This can be done by
means of tumour markers (AFP and β-HCG, LDH) and
spiral CT (computed tomography) scanning of the lungs,
the retroperitoneum and pelvis. On indication
(anamnestic complaints of the cerebrum and/or sharply
elevated β-HCG), CT scanning of the cerebrum is
conducted. The roles and/or additional value of magnetic
resonance imaging (MRI) and positron emission
tomography (PET) are currently under investigation [20].
At the University Medical Center Groningen, the
Netherlands (UMCG), patients with TGCT are staged
according to the Royal Marsden classification (Table 2).
Patients with stage I have no radiological or biochemical
evidence of metastases. Patients with stages II to IV have
metastasized disease. These patients are subsequently
classified according to the prognostic factors formulated
by the International Germ Cell Cancer Collaborative
Group (IGCCCG) (Table 1) and a treatment plan is
drawn up on the basis of the subgroup classification
(good/intermediate/poor) [4].
Treatment
Stage I disease (=non-metastasized disease)
About half of the patients with a non-seminoma
present with stage I disease. Presently, the treatment
comprises radical orchidectomy with high ligation of
the spermatic cord, blood vessels and lymph vessels,
followed by regular outpatient visits (wait-and-see
policy) or modified unilateral nerve-sparing
retroperitoneal lymph node dissection. The UMCG has
been applying the wait-and-see policy to patients with
stage I disease since 1982 [21]. In the meantime,
world-wide consensus has been reached about the
treatment for stage I non-seminoma patients in the
low-risk group (i.e. histological examination does not
show any vascular invasion of the tumour). These
patients have a 15% risk of TGCT relapse; thus the
wait-and-see policy is justified and comprises regular
outpatient visits for 5 years after orchidectomy with
physical examination, tumour marker analysis and
frequent radiological investigation.
There is a great deal of discussion about the current
treatment policy for patients with stage I non-seminoma
in the high-risk group (i.e. histopathological
investigation shows vascular invasion). Unilateral nerve-
sparing retroperitoneal lymph node dissection (RPLND)
or adjuvant chemotherapy leads to a considerable
reduction in the risk of relapse of about 5%. However,
the disadvantages of RPLND (loss of ejaculatory
function) or chemotherapy (toxicity) must be taken into
consideration. The UMCG still applies the wait-and-
see policy to these high-risk patients. In the UK and
many other European countries, the preferred
Martijn F. Lutke Holzik, Rolf H. Sijmons, Josette E.H.M. Hoekstra-Weebers, Dirk Th. Sleijfer, Harald J. Hoekstra
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approach for high-risk patients is often to administer
two courses of adjuvant chemotherapy, whereas in the
USA it is the trend to perform nerve-sparing unilateral
RPLND [2, 3]. Which treatment policy is the best for
these so-called ‘high-risk’ patients is unknown.
About 75% of patients with seminoma have stage
I disease. The standard treatment after orchidectomy
is radiotherapy of the retroperitoneal para-aortic lymph
nodes with a total dose of 20 Gy. In this way the
relapse rate is reduced to 1-3% [2]. The advantage of
para-aortic radiotherapy (while excluding the ipsilateral
lymph nodes) is less gastrointestinal and gonadal
toxicity. As an alternative to radiotherapy, adjuvant
chemotherapy can be administered. The latter
approach results in the same relapse rates [22]. A wait-
and-see policy alone would lead to relapse rates of
15 to 20% and is less suitable, because there are no
sensitive tumour markers for seminoma and the patient
would therefore have to undergo frequent radiological
investigation [2, 3].
Metastasized disease
Patients with stage IIa and IIb seminoma receive
radiotherapy with a total dose of 30 and 36 Gy,
respectively. In contrast to stage I seminoma, the
ipsilateral iliac lymph nodes are also included in the
treatment volume (dog-leg field) in patients with stage
II seminoma. This approach achieves 6-year relapse-
free survival of 95% in stage IIa patients and 89% in
stage IIb patients. Alternative treatments to radiotherapy
can be considered in stage IIb patients, for example 
3 courses of BEP (bleomycin, etoposide and cisplatin)
or 4 courses of EP (etoposide and cisplatin) [2, 3].
Treatment for patients with stage IIc-IV metastasized
seminoma and with stage II-IV metastasized non-
seminoma comprises chemotherapy in accordance
with the prognostic factor classification. In the good
prognosis group, patients with non-seminoma/
seminoma receive chemotherapy in the form of 
3 courses of BEP or 4 courses of EP. Patients in the
intermediate and poor prognosis groups are treated
with 4 courses of BEP [2, 23, 24].
Surgery after chemotherapy
After completion of chemotherapy, patients with 
a metastasized tumour (TGCT) at the UMCG undergo
restaging with the aid of serum tumour marker analyses
(as described above) and spiral CT scanning of the
lungs and retroperitoneum. When radiological
investigation shows residual disease after completion
of chemotherapy in patients with seminoma, surgical
resection is not performed, but instead the abnormality
is followed radiologically. Generally, a new indication
will arise for chemotherapy or radiotherapy, which if
necessary is combined with surgical resection of 
the residual tumour. Presently, positron emission
Table 2. Royal Marsden staging classification of testicular germ cell tumours
Stage Criteria
I no evidence of metastases
IM no clinical evidence of metastases, but persistent elevation of serum tumour markers AFP and/or hCG
II infradiaphragmatic lymph node metastases
IIA metastases <2 cm in diameter
IIB metastases 2-5 cm in diameter
IIC metastases >5 cm in diameter
III supradiaphragmatic lymph node metastases; status A, B, C as for stage II
IV extra lymphatic metastases
L1 ≤3 lung metastases
L2 >3 lung metastases, all ≤2 cm in diameter
L3 >3 lung metastases, one or more >2 cm in diameter
H+, Br+, Bo+ liver, brain, or bone metastases
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tomography (PET) scanning can be applied to help
identify viable cancer [25].
After patients with non-seminomatous TGCT have
completed chemotherapy, there is no indication for
surgical resection when they do not show any residual
disease, or the residual abnormality is smaller than 
1 cm, the tumour markers have normalised and mature
teratoma is absent from the primary tumour. Follow-
up is then conducted on the basis of tumour markers.
However, when residual (abdominal/pulmonary)
disease is identified, surgical resection must be
performed on the residual retroperitoneal tumour mass
(RRRTM), or local resection in the case of residual
pulmonary tumour tissue. When residual tumour
persists after completion of chemotherapy and the
tumour markers remain high, an individual treatment
plan must be drawn up: salvage chemotherapy or
salvage surgery.
In patients with non-seminomatous TGCT, it is not
possible to predict the histology of the residual tumour.
After surgical resection, histological examination shows
that the mass consists of necrosis in 45% of cases, mature
teratoma in 40%, viable tumour tissue in 10% and non-
germ cell malignancies in the remaining 5% [26].
When the resected residual tumour only contains
necrosis or mature teratoma, no further treatment is
necessary and the patient has an excellent prognosis.
However, when viable tumour tissue is present, the
prognosis is less favourable and depending on factors
such as the initial prognostic classification (Table 1),
the volume (percentage) of residual viable cancer
and the completeness of the resection, it may be
necessary to administer adjuvant salvage
chemotherapy [27].
The clinical significance of mature teratoma in the
residual tumour is not yet completely clear and it is
impossible to predict the course that can be expected
from mature teratoma left in situ. In the literature,
“growing teratoma” is a well-known phenomenon and
it can lead to (very) late tumour recurrence. In addition,
there is a risk that mature teratoma will de-differentiate
into a non-germ cell malignancy (e.g. sarcoma). In
such cases, the prognosis of the patient is far less
favourable. Radical surgery is the only curative
treatment option for these non-germ cell tumours.
When the primary TGCT contains elements of
mature teratoma, there is a greater chance that the
residual tumour will also contain teratomatous elements.
Therefore, at the UMCG, all patients with elements of
teratoma in the primary tumour undergo laparotomy
and partial retroperitoneal dissection at the “original”
tumour site after chemotherapy, even when there are
no radiological signs of residual disease [26].
Familial, hereditary and syndromic
aspects
Family history
1-3% of patients with TGCT report an affected first-
degree relative, a proportion higher than would be
expected by chance [28-38]. The largest number of
reported cases in a family is five [39], but most familial
clustering consists of relative pairs such as two affected
brothers and to a smaller extent an affected father and
son [30, 40]. Brothers of patients with TGCT have 
a relative risk of TGCT of 8-10, and for father-son the
relative risk is 4-6 [30, 31, 36].
Racial differences and geographical clustering
Geographical clustering of TGCT [41] and racial
differences in the incidence of this disease could
indicate a genetic component in the cause of the
disease. The highest incidence is seen in white people
of northern European descent, whereas people of
African or Asian descent seem to have a universally
low incidence of TGCT [40, 42-44]. Observed
differences in incidence persisting after migration argue
in favour of genetic rather than exogenous risk factors.
Bilateral TGCT
Heimdal and co-workers [31] found that 2.8% of
patients with TGCT who did not have a family history
had bilateral disease compared with 9.8% of those
with a positive family history. Somatic mutations of the
KIT oncogene occur in a very high proportion (95%)
of tumours from patients with bilateral disease
compared with a smaller proportion (3%) of tumours
from those with unilateral disease [45]. When both
tumours from bilateral cases could be assessed, an
identical KIT mutation was observed. Patients with 
a family history of TGCT had a similar frequency of
KIT mutations in unilateral TGCT compared with
sporadic cases. Interestingly, in patients with bilateral
disease and a family history of TGCT only 28% of
tumours showed KIT mutations, suggesting that bilateral
disease in the context of familial TGCT has a different
pathogenesis from sporadic bilateral cases [46].
Cryptorchism and other disorders of testicular differentiation
in patients and relatives
Cryptorchism and other testicular abnormalities
such as atropy, infertility, hydrocele and inguinal hernia
are risk factors for TGCT [47-50]. Forman and co-
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workers [30] showed that the frequency of cryptorchism
in patients with TGCT did not differ between those with
or without a positive family history. From a different
perspective, Tollerud and colleagues [37] showed 
that cryptorchism or inguinal hernia occurred in 
a significantly greater proportion of first-degree male
relatives of patients with a family history of TGCT than
of relatives of patients with sporadic TGCT or of
controls. The high prevalence of cryptorchism, inguinal
hernias, and hydrocele in these families suggests that
an underlying shared genetic defect might be present.
Up to approximately 8% of infertility in the general male
population can be explained by the presence of
constitutional deletions of part of the long arm of the
Y chromosome (Yq11), referred to as the azoospermia
factor (AZF) region (subdivided into AZFa to AZFd) [51-
53]. AZFc deletions are the most commonly found
(60%). Although most of the AZF deletions observed
in infertile men are new (de novo) mutations, they have
been inherited in some cases from (apparently fertile)
fathers, and 0.4% of fertile men in the general
population appear to carry an AZF deletion [52].
Foresta et al. recently observed a particularly high
percentage of 27.5% AZF (a-c) deletions in patients
with low sperm counts as well as unilateral cryptorchism
[54]. Cryptorchism is an acknowledged risk factor for
TGCT and is one of the postulated other possible
manifestations of TDS. Taken together, these
observations suggests that, at least from a theoretical
point of view, constitutional AZF deletions might be one
of the genetic contributors to the development of TDS
and thereby of TGCT and other TDS manifestations.
We investigated the frequency of Y chromosome
deletions in the AZF region, in a series of fertile, as well
as infertile, patients with TGCT, but did not find any
deletions [55]. However, more recently a novel 
Y-chromosome 1.6-MB deletion was reported, referred
to as gr/gr, and is associated with spermatogenic failure
[56]. This deletion is much smaller than the deleted
AZF region studied previously and removes only part
of the AZFc region, including copies of DAZ and a copy
of CDY1, as well as other transcription units. Nathason
et al. recently described an association between 
gr/gr deletions and TGCT. Familial TGCT patients had 
a threefold increased risk of having these gr/gr
deletions [57].
Risk of other tumours in relatives of TGCT patients 
Many studies [38, 58] confirm a high incidence of
TGCT in relatives of patients with TGCT. In contrast,
there appears to be no excess risk of other cancer types
in first-degree relatives of patients with TGCT, with the
exception of patients’ mothers, who have are at an
increased risk of developing lung cancer, non-
endometrial uterine cancer, soft tissue tumours and
melanoma [29].
Syndromic aspects
Patients with Klinefelter’s syndrome (47 XXY) have
a very high risk of mediastinal, (extragonadal) germ-
cell tumours, and some may also be at risk of
developing TGCT [59]. About 8% of patients with such
tumours have Klinefelter’s syndrome [60]. Patients with
XY, or 45,X/46,XY gonadal dysgenesis have a greatly
increased risk of germ-cell tumours [59, 61]. Patients
with Down’s syndrome (trisomy 21) might also be at
increased risk of TGCT but the numbers are too small
for firm conclusions to be drawn [62, 63]. The presence
of TGCT in a hereditary syndrome might be an
indication of a hereditary predisposition to TGCT.
Owing to the rarity of most of these disorders and the
scarce reports of their occurrence in combination with
TGCT, there is no statistical proof of an association of
TGCT with these disorders. However, as our literature
survey demonstrated [64], it is striking that in a subset
of these disorders there is also a range of defects in
urogenital differentiation, which suggests that TGCT
in these disorders is indeed a further complication of
such a differentiation defect, as postulated in the TDS
model of Skakkebaek and colleagues (Figure 1) [12].
Twin studies
Swerdlow and colleagues [65] found that the risk
of TGCT was raised in twin brothers of patients with
TGCT (relative risk 37.5, 95% CI 12.3–115.6) and
was greater in monozygotic (76.5) than dizygotic (35.7)
twins. This relative risk is several times that found in
non-twin brothers (although the confidence limits are
wide due to the small numbers) but it does imply that
the genetic element for risk is far larger for TGCT than
for most other cancers. Other twin studies on TGCT
have not had sufficient numbers of concordant twin
pairs and could not confirm this result. Several studies
have confirmed a higher frequency of TGCT in
dizygotic twins than in singletons and monozygotic
twins. It has been postulated that abnormally high
oestrogen concentrations in pregnancy predispose the
developing gonad to TGCT in adulthood [66].
Interestingly, the concentration of circulating oestrogen
is significantly higher in pregnancies with dizygotic than
in those with monozygotic twins or singletons, and
therefore might have been a contributory causative
factor [65, 67, 68].
Hereditary Cancer in Clinical Practice 2008; 6(1)10
Modelling studies
Two studies so far have tried to identify the mode
of inheritance of TGCT susceptibility genes. One was
based on the frequency of bilateral TGCT [69], and
the other was a segregation analysis on a group of
Norwegian and Swedish families [70]. The latter study
reported that the familial clustering was best accounted
for by a major gene for TGCT with a recessive mode
of inheritance. Under this recessive model, 7.3% of
men in the population carry the mutant allele and 0.1%
are homozygous. According to the calculations by the
authors, the lifetime risk of development of TGCT in
homozygous men is 43% [70]. Based on a comparison
of the distribution of age at diagnosis between patients
with bilateral TGCT and familial cases (i.e. those likely
to be genetically determined), Nicholson and Harland
[69] assumed in their model that the increased risk was
due solely to genetic susceptibility. These authors
estimated that about a third of general patients with
TGCT carry the susceptibility genotype and that the
penetrance is 0.45. Calculations with these values
showed that a recessive disease model showed a better
fit with the observed risks for brothers (2.2%) and
fathers (0.5%) of patients with TGCT than a dominant
disease model. The frequency of the susceptibility allele
in the recessive model was estimated to be 5%. The
higher relative risk for brothers than for father-son pairs
is compatible with contributions from a recessive mode
of inheritance, but since the early 1990s the incidence
of TGCT has increased sharply, maintenance of fertility
after treatment for TGCT has improved greatly, and
the introduction of cisplatin-based chemotherapy has
substantially lowered the number of deaths from TGCT
[71-73]. These changes may lead to a situation in
which updated relative risk estimates for father-son
pairs turn out to be higher than previous ones. In
addition to a recessive model, a dominant form of
inheritance as well as an X-linked one could not be
excluded. Because a proportion of bilateral cases are
caused by early somatic mutations in KIT and because
there is likely to be more than one TGCT susceptibility
gene, susceptibility to TGCT is probably more complex
than suggested by either of these models.
Association studies and haplotype analyses
Previous studies have shown that HLA factors might
be associated with the development of TGCT. In
particular, consistent associations were found with the
HLA class II antigens. No association was found with
the HLA-A and HLA-C regions, and inconsistent
associations were found with the HLA-B region [74].
The first HLA genotyping study by Özdemir and
colleagues [75] in 55 Japanese patients showed two
associations: one HLA susceptibility allele and one HLA
protective allele (relative risk 3.26 and 0.26
respectively). Our own, larger, genotyping study on the
HLA class II region of chromosome 6p21 on 151
patients from the northern part of the Netherlands
could not replicate this association [74]. The
association between TGCT and HLA class II alleles
either does not exist, or is much weaker than the earlier
report suggested. To date, no convincing associations
have been shown between TGCT and a genetic
polymorphism.
Linkage analysis and genome-wide screens
The International Testicular Cancer Linkage
Consortium (ITCLC) has the largest collection of TGCT
pedigrees with two or more cases of TGCT in a family.
Their first evidence for a TGCT susceptibility gene was
for the X chromosome [76]. The analysis on 99
pedigrees compatible with X linkage (no male-to-male
transmission) yielded a heterogeneity LOD score of
2.01 on chromosome Xq27. Families with at least one
case of bilateral disease showed strong evidence of
linkage to a locus on Xq27 (heterogeneity LOD score
= 4.76) and were more likely to show linkage to the
X chromosome than families without a bilateral case.
This proposed susceptibility gene on chromosome
Xq27 was referred to as TGCT1 [76]. The ITCLC
reported preliminary results on an additional 25
pedigrees compatible with X linkage but the set was
too small for any firm conclusions to be drawn [77].
In our own study we did not find an association
between Xq27 and familial TGCT, cryptorchism or
bilateral TGCT [78]. Interestingly, we did observe an
association between the subset of TGCT cases without
a family history of TGCT or cryptorchism and specific
alleles for the marker DXS1193 both by allelic
association analysis and by the haplotype sharing
statistics. The frequency of all minor alleles was
increased among these patients compared to controls:
13.9 vs. 3.4%, respectively. The risk of developing
sporadic TGCT without cryptorchism for an individual
who has one of the minor alleles was estimated to be
4.7 (99.57% CI: 1.1-19.6). This suggests that in our
Dutch population one or more low frequent mutations
of an Xq27-linked gene contribute to TGCT
development but not to cryptorchism. Alternatively,
particular genotypes in this region possibly protect the
normal population from developing TGCT. Further
analyses on single nucleotide polymorphism (SNPs) in
candidate genes in this region should be performed
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to identify the causal gene and to unravel the nature
of its causality. With respect to autosomal loci, the latest
ITCLC study reported on a genome-wide screen in 
a total of 179 pedigrees and failed to detect any LOD
scores greater than 3 in any autosomal locus.
Suggestive evidence for linkage has been obtained for
several autosomal regions including 3q27, 12q12-q13,
16p13, and 18q22-qter [77]. The power to detect
some or all of the susceptibility genes for TGCT will
depend greatly on the degree of genetic heterogeneity
of this disease. Continued identification and recruitment
of families into this linkage study will be crucial to the
efforts to identify these genes.
Discussion and future perspectives
The incidence of TGCT has doubled over the last
40 years. This increase is unlikely to be caused by
genetic predisposition alone and environmental factors
most likely play an important role as well. Although
TGCT is an infrequent disease and it is highly curable,
it is still important to unravel the environmental risk
factors as well as genetic predisposition for TGCT. Early
identification of men with increased risk for inherited
TGCT might lead to early detection and improved
treatment outcome. In the current literature there are
no data on the clinical behaviour (or prognosis) of
TGCT in patients with familial TGCT. However, clinical
observation does not suggest any differences in survival
and presently there is no reason to expect that familial
TGCT has a different outcome than sporadic TGCT.
Thus identifying TGCT in genetically predisposed men
at an earlier stage is expected to improve survival
similar to sporadic cases. Early detection could
theoretically be achieved by ultrasound of the testes,
palpation (routine testicular self examination) and/or
by measuring tumour markers. Presently, however, there
is no proof that men who routinely examine their testes
are more likely to detect earlier stage tumours or
improve their prospects for survival [79] and there are
no data on possible benefits of clinical surveillance in
familial TGCT. Treatment of TGCT may be further
optimized using new insights in the oncogenetic
pathways involved, possibly reducing the need for toxic
chemotherapy and radiotherapy. The unravelling of the
genetic pathway of TGCT might result in the
opportunity to develop gene therapy. There are some
trials in other types of cancer with promising results.
The use of genetically modified autologous tumour
cells appears to be a valuable approach for cancer
therapy. Further studies are required to determine
whether effects on immune activation will result in
actual clinical benefit for patients [80].
Although circumstantial evidence points to the
existence of TGCT predisposition, no germ line gene
mutations have yet been identified that confer a high
risk of developing TGCT. The question arises whether
such mutations exist at all or whether genetic
predisposition to TGCT will turn out (as the gr/gr
deletions did) to consist of a range of mutations, each
with only relatively weak effects. One barrier to
resolving this issue is the fact that large families with 
a strong family history of TGCT are rare. The ITCLC,
which has done an impressive job of collecting a series
of 459 pedigrees, has not been able to firmly identify
genomic regions associated with high TGCT risk so far
and suggests that susceptibility to TGCT might be
determined through multiple loci as opposed to 
a single locus. Possibly, very strongly inherited TGCT
predisposition does not exist. Unfortunately, linkage
analysis, in contrast to association studies, is not 
a powerful tool for gene detection when mildly
predisposing frequent genetic variants play a role [81].
With 459 pedigrees, of which the ITCLC examined only
237, because the rest were considered not well
sampled, only a relative risk of 5 or larger for carriers
of a genetic variant (frequency of 15%) can be
detected. To detect a relative risk of 2, which is realistic
in complex human diseases, one would need to study
at least 2000 pedigrees to have 80% power to detect
such a genetic variant. On the other hand, it cannot
be excluded that (part of) the familial clusters can still
be attributed to different, rare, strongly predisposing
gene mutations present in subsets of families, that,
because of their low frequency in the population, may
very well escape detection in such relatively small
linkage studies. It may be interesting to perform linkage
studies in a subset of familial TGCT patients with
urogenital malformations (such as hypospadia,
cryptorchism, bilateral disease), because in this
subgroup of patients (identical phenotypes) it is very
possible that they share a causative gene which results
in urogenital malformations as well as TGCT
(Skakkebaek model).
Recently the genetic defect in mouse strain
129.MOLF-Chr19 chromosome substitution strain,
known to develop TGCTs at a high frequency (70-80%),
was reported [82]. A germ line mutation in the dead
end gene (DND1) was found to cause this high tumour
risk (and some testicular and spermatogenic
abnormalities) [57]. Very little is known about the human
homologue of DND1 and it is therefore worthwhile to
study its possible association with human TGCT.
The collection of more families with TGCT will
facilitate genetic studies. Some hospitals systematically
collect DNA from their cancer patients in a prospective
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way in order to expand the material for genetic studies.
The Icelandic deCODE initiative (www.decode.com)
takes this approach a large step further by linking
genealogical data with disease status and DNA
markers in their national population. Such approaches
are to be encouraged from a purely scientific point of
view; however, privacy and other ethical and legal
issues involved in these approaches need to be
addressed very thoroughly. International collaboration
will be facilitated if DNA and patient data collecting
are performed according to (to be developed)
international standards. The HapMap project, 
a partnership of scientists and funding agencies all
over the world to develop a public resource that will
help researchers find genes associated with human
disease, is a good example (www.hapmap.org).
Not only are study populations expanding through
collaborative efforts; statistical techniques and insights
into cancer biology and its resulting molecular tools
are evolving as well. Recently, the scope of genetic
study of TGCT has been extended to include the role
of naturally occurring micro RNAs (miRNAs). Normally
miRNAs function as regulators of genetic pathways by
manipulating translational regulation. Some of these
miRNAs (miRNA-372 and 373) were shown to allow
tumorigenic growth. As they have also been observed
to be expressed in human seminomas and non-
seminomas, but not in normal testicular tissue, it has
been suggested that these miRNAs may represent 
a new class of oncogenes involved in TGCT
development [18]. Time will tell whether miRNAs play
a role in (testicular) cancer predisposition.
Should future studies identify clinically important
TGCT-predisposing mutations, then testing for these
mutations might be welcomed by a substantial subset
of TGCT patients and families, as has been the case for
many families with common hereditary tumour
syndromes. Research on early detection techniques for
TGCT in high-risk men will be necessary. Although many
studies have looked into the psychosocial aspects and
requirements for genetic testing programmes in these
syndromes, very little is known with respect to testing in
the setting of TGCT. Research on early detection
techniques for TGCT in high-risk men will be necessary.
As in any other new genetic testing programme, testing
would need to be performed in a research setting first,
where medical as well as psychosocial issues would need
to be carefully monitored.
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